A UK-based KOL discusses the treatment pathway of HR+/HER2- breast cancer with an emphasis on disease burden for early-stage patients and the additional toxicities of CDK4/6 inhibitors in the adjuvant setting. The KOL also highlights the issues surrounding the sequential use of ADCs and the toxicity profiles of pipeline therapies. 

This interview was conducted on Sept. 3, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.